The 10-second takeaway
For the quarter ended June 30 (Q4), ResMed met expectations on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue increased and GAAP earnings per share grew significantly.
Margins grew across the board.
ResMed logged revenue of $371.9 million. The 10 analysts polled by S&P Capital IQ predicted net sales of $370.3 million on the same basis. GAAP reported sales were 8.8% higher than the prior-year quarter's $341.9 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.54. The 10 earnings estimates compiled by S&P Capital IQ averaged $0.49 per share. GAAP EPS of $0.53 for Q4 were 43% higher than the prior-year quarter's $0.37 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 60.9%, 210 basis points better than the prior-year quarter. Operating margin was 24.1%, 390 basis points better than the prior-year quarter. Net margin was 20.7%, 360 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $340.3 million. On the bottom line, the average EPS estimate is $0.47.
Next year's average estimate for revenue is $1.49 billion. The average EPS estimate is $2.02.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 171 members out of 184 rating the stock outperform, and 13 members rating it underperform. Among 53 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 51 give ResMed a green thumbs-up, and two give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on ResMed is outperform, with an average price target of $34.25.
- Add ResMed to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.